drugset
drugset / Trial / NCT06147518

To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis

NCT06147518 ↗

Unknown 240 enrolled Institute of Liver and Biliary Sciences, India
RandomizedParallel-groupOpen-labelTreatment

Summary

Diabetes prevalence is increasing among cirrhotics and use of OAD in cirrhotics is limited because of risk of hypoglycaemia and other adverse effects, therefore in this study we would be using OAD in the form of Sitagliptin or Dapagliflozin to look for glycemic response as well as to look for other benefits such as weight reduction and improvement in lipid parameters.

Timeline

Start
2023-12-20
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg —
Comparator Sitagliptin Small molecule 100 mg —
Background Metformin Small molecule 1 g —
Background Metformin Small molecule 1.5 g —

Indications

cirrhosis of liver